The role of IVIg treatment in severe pemphigus vulgaris

Authors:

Abstract
Background  High‐dose intravenous immunoglobulin (IVIg) has become a part of the treatment armentarium in pemphigus vulgaris (PV). Some consider IVIg as an adjuvant steroid sparing agent in PV, while others as disease modifying that can be used as monotherapy.Methods  We report our experience with a series of 12 PV patients with severe disease treated with IVIg as an adjuvant therapy.Results  Ten of 12 patients (83%) showed response to six cycles of IVIg, six (50%) having complete remission and four (33%) having a partial response. This response rate is concordant with previous reports. The therapy was well tolerated. In all 12 patients, treatment with IVIg allowed a gradual reduction of prednisone dose compared with baseline levels.Conclusion  IVIg treatment was beneficial as a steroid sparing agent in our series of patients with severe PV.

This publication has 14 references indexed in Scilit: